We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp
NYMX

Delisted

NYMX was delisted on the 6th of July, 2023.

Back to rankings

51 hedge funds and large institutions have $4.03M invested in Nymox Pharmaceutical Corp in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $60K | Put options by funds: $20K

14% less funds holding

Funds holding: 59 → 51 (-8)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

38% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 21

70% less capital invested

Capital invested by funds: $13.4M → $4.03M (-$9.34M)

Holders
51
Holders Change
-8
Holders Change %
-13.56%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
14
Closed
21
Calls
$60K
Puts
$20K
Net Calls
+$40K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$568K
2
E
Ergoteles
New York
+$345K
3
TEE
Tibra Equities Europe
United Kingdom
+$280K
4
HF
HRT Financial
New York
+$223K
5
ECM
ExodusPoint Capital Management
New York
+$137K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.28M
2
State Street
State Street
Massachusetts
-$1.16M
3
Northern Trust
Northern Trust
Illinois
-$826K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$485K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$453K

NYMX Hedge Fund Activity: Q2 2021 in Review

51 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2021, worth a combined $4.03M — down 70% from $13.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of NYMX and 13 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, adding an estimated $568K. The largest seller was BlackRock, cutting an estimated $3.28M.

  • 51 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2021, down from 59 in Q1 2021.
  • Funds reported $4.03M of Nymox Pharmaceutical Corp stock for Q2 2021, down 70% quarter-over-quarter.
  • 13 funds opened new Nymox Pharmaceutical Corp positions in Q2 2021 and 21 closed out, a net change of -8 holders.
  • The largest Nymox Pharmaceutical Corp buyer in Q2 2021 was Millennium Management, an estimated $568K added.
  • The largest Nymox Pharmaceutical Corp seller in Q2 2021 was BlackRock, an estimated $3.28M sold.

Based on aggregated 13F filings for Q2 2021.